Navigation Links
Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
Date:3/13/2009

on, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to successfully commercialize its lead product candidate, Intermezzo(R). If approved, Intermezzo(R) will be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA), which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the Company's website at: www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the ability of merger proceeds to be sufficient to successfully commercialize Intermezzo(R) and the potential for Intermezzo(R) to be the first commercially available sleep aid specifically designed for use in the middle of the night and the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, a significant delay in FDA approval of Intermezzo(R); unanticipated addition
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Integrated ... wellness, is opening another new medical specialty practice through ... IMA Cardiology will be located within the company’s ... Abbud and Dr. Isaac Tawfik of American Heart Center, ... The new practice will offer Integrated Medicine Alliance patients ...
(Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
(Date:9/30/2014)... Elevate , the latest product from Blue Start ... of the gym by providing natural ingredients that boost brain ... Michaels, prompting an investigative review. , “When it comes ... simply just don’t have the ability to perform the way ... the motivation to finish a project, or even feeling like ...
(Date:9/30/2014)... 30, 2014 Hospice & Palliative ... “In Celebration” gala, honoring three outstanding individuals for ... striving to provide extraordinary and dignified comfort, care ... serious or life-limiting illness. , The event was ... NY and recognized William (Bill) J. McGuinness, Director ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dr. Karl ... knee pain program of care that is dramatically ... , His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, ... knee. It also addresses sources of inflammation, neurology of ... the “neurokinetic chain” from the brain to the spine, ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3
... computer tomography (CT) scans, imaging plays an important ... high-quality images often requires advanced technology and expertise, ... launches its preparatory phase today, aims to provide ... imaging technologies at all levels of biological and ...
... News) -- A problem in the lining of blood vessels ... according to a new study. The condition, called endothelial ... the layer of cells that line blood vessels. Nitric oxide ... improves blood flow and the delivery of oxygen and nutrients ...
... today at the annual meeting of the Radiological Society ... ionizing radiation from imaging procedures and efforts under way ... on the risks and benefits of medical imaging. ... chairman of the Department of Diagnostic Radiology at Yale ...
... , WEDNESDAY, Dec. 1 (HealthDay News) -- ... new study contends. The study included nearly 600 ... disorder that causes severe pain and diarrhea. The ... the study and 19 percent of them were found ...
... A U.S. Food and Drug Administration advisory committee on Wednesday ... prostate cancer, the third-highest cancer killer of men. ... of Merck,s Proscar outweighed its benefits, according to the ... voted 14-2, with two abstentions, against GlaxoSmithKline,s Avodart. Both drugs ...
... Ore. Young women veterans are nearly three times ... new research published by researchers at Portland State University ... The paper, "Self-Inflicted Deaths Among Women With U.S. ... 2010 issue of Psychiatric Services , a journal ...
Cached Medicine News:Health News:Better imaging from bench to bedside 2Health News:New Piece of Alzheimer's Puzzle Identified 2Health News:Expert panel addresses safety in medical imaging 2Health News:Expert panel addresses safety in medical imaging 3Health News:Study Suggests Link Between Crohn's Disease and PTSD 2Health News:FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer 2Health News:Suicide rate among young women veterans more than twice that of civilians 2
(Date:9/30/2014)... Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a ... commercialization of prescription ophthalmic pharmaceuticals, announced today that it ... Growth Capital, Inc. (NYSE: HTGC ) (Hercules). ... the Loan and Security Agreement that Alimera,s subsidiary in ... Limited, entered into with Hercules in April of this ...
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... DIEGO, June 7, 2011 Tocagen Inc. ... high grade glioma, such as those with glioblastoma multiforme ... Toca 511. The multicenter, open-label study is ... of Toca 511 administered intratumorally followed by cycles of ...
... 2011 Topaz Pharmaceuticals Inc., a privately held specialty ... Drug Administration (FDA) accepted for filing the New Drug ... as a treatment for head lice infestations in children ... transition of the Company from the development phase as ...
Cached Medicine Technology:Tocagen's First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 3
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: